Literature DB >> 18509632

What oncologists need and require from nuclear medicine.

M A Pantaleo, S Fanti, M Nannini, S Boschi, C Nanni, A Maleddu, D Rubello, G Biasco.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18509632     DOI： 10.1007/s00259-008-0825-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  39 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 2.  Monitoring cancer treatment with PET/CT: does it make a difference?

Authors:  Wolfgang A Weber; Robert Figlin
Journal:  J Nucl Med       Date:  2007-01       Impact factor: 10.057

Review 3.  Application of PET/CT in the development of novel anticancer drugs.

Authors:  David S Boss; Renato Valdes Olmos; Michiel Sinaasappel; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2008-01

4.  Early tumor response to Hsp90 therapy using HER2 PET: comparison with 18F-FDG PET.

Authors:  Peter M Smith-Jones; David Solit; Farzana Afroze; Neal Rosen; Steven M Larson
Journal:  J Nucl Med       Date:  2006-05       Impact factor: 10.057

5.  Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.

Authors:  Cristina R Antonescu; Peter Besmer; Tianhua Guo; Knarik Arkun; Glory Hom; Beata Koryotowski; Margaret A Leversha; Philip D Jeffrey; Diann Desantis; Samuel Singer; Murray F Brennan; Robert G Maki; Ronald P DeMatteo
Journal:  Clin Cancer Res       Date:  2005-06-01       Impact factor: 12.531

6.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

Authors:  H Young; R Baum; U Cremerius; K Herholz; O Hoekstra; A A Lammertsma; J Pruim; P Price
Journal:  Eur J Cancer       Date:  1999-12       Impact factor: 9.162

7.  Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec).

Authors:  Kun-Eek Kil; Yu-Shin Ding; Kuo-Shyan Lin; David Alexoff; Sung Won Kim; Colleen Shea; Youwen Xu; Lisa Muench; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2007-02       Impact factor: 2.408

8.  Clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Authors:  Robert F Ozols; Roy S Herbst; Yolonda L Colson; Julie Gralow; James Bonner; Walter J Curran; Burton L Eisenberg; Patricia A Ganz; Barnett S Kramer; Mark G Kris; Maurie Markman; Robert J Mayer; Derek Raghavan; Gregory H Reaman; Raymond Sawaya; Richard L Schilsky; Lynn M Schuchter; John W Sweetenham; Linda T Vahdat; Rodger J Winn
Journal:  J Clin Oncol       Date:  2006-12-08       Impact factor: 44.544

9.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors:  Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

10.  Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.

Authors:  Mario Scartozzi; Italo Bearzi; Chiara Pierantoni; Alessandra Mandolesi; Fotios Loupakis; Alberto Zaniboni; Vincenzo Catalano; Antonello Quadri; Fausto Zorzi; Rossana Berardi; Tommasina Biscotti; Roberto Labianca; Alfredo Falcone; Stefano Cascinu
Journal:  J Clin Oncol       Date:  2007-09-01       Impact factor: 44.544
View more
  2 in total

1.  Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.

Authors:  Maria A Pantaleo; Eyal Mishani; Cristina Nanni; Lorena Landuzzi; Stefano Boschi; Giordano Nicoletti; Samar Dissoki; Paola Paterini; Pier Poalo Piccaluga; Filippo Lodi; Pier-Luigi Lollini; Stefano Fanti; Guido Biasco
Journal:  Mol Imaging Biol       Date:  2010-12       Impact factor: 3.488

2.  [Prognostic significance of changes of tumor epidermal growth factor receptor expression after neoadjuvant chemoradiation in patients with rectal adenocarcinoma].

Authors:  J Dvorak; V Sitorova; A Ryska; I Sirak; I Richter; J Hatlova; A Ferko; B Melichar; J Petera
Journal:  Strahlenther Onkol       Date:  2012-08-01       Impact factor: 3.621
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.